Emerging Biotechs Can Speed Development with Tailored Global Trial Strategies, Panel Says

A panel of biotech chief medical officers and CRO executives discussed how small biotechs can accelerate clinical development by using fit-for-purpose global trial designs.

They highlighted both the advantages, such as broader patient access, and the hurdles, including regulatory differences and logistical complexity when operating across multiple regions.

The conversation covered when to initiate studies in various countries and how to align data collection to support later approval submissions.

Finally, the speakers emphasized the need to respect local cultures and health-system structures to manage trials effectively and keep timelines on track.